Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticlePediatric Rheumatology

Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis

Consuelo M. López De Padilla, Cynthia S. Crowson, Molly S. Hein, Richard S. Pendegraft, Michael A. Strausbauch, Timothy B. Niewold, Floranne C. Ernste, Erik Peterson, Emily C. Baechler and Ann M. Reed
The Journal of Rheumatology January 2017, 44 (1) 117-124; DOI: https://doi.org/10.3899/jrheum.160293
Consuelo M. López De Padilla
From the Division of Rheumatology, Department of Pediatrics, Mayo Clinic; Division of Rheumatology and Division of Biomedical Statistics and Informatics, Department of Health Science Research, Mayo Clinic; Department of Surgical Research, Mayo Clinic; Division of Rheumatology and Department of Immunology, Mayo Clinic; Division of Rheumatology, Department of Internal Medicine and Department of Pediatrics, Mayo Clinic College of Medicine, Rochester; Division of Rheumatic and Autoimmune diseases, Department of Medicine, University of Minnesota, Minneapolis, Minnesota; Department of Pediatrics, Duke Children’s Hospital, Duke University Medical Center, Durham, North Carolina, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia S. Crowson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Molly S. Hein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard S. Pendegraft
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Strausbauch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy B. Niewold
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Floranne C. Ernste
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Peterson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily C. Baechler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann M. Reed
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ann.reed@duke.edu
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To identify shared and differential molecular pathways in blood and affected muscle between adult dermatomyositis (DM) and juvenile DM, and their association with clinical disease activity measures.

Methods. Gene expression of transcription factors and cytokines involved in differentiation and effector function of T cell subsets, regulatory T cells and follicular Th cells, were analyzed in the blood from 21 newly diagnosed adult and 26 juvenile DM subjects and in 15 muscle specimens (7 adult and 8 juvenile DM) using a custom RT2 Profiler PCR Array. Disease activity was determined and measured by established disease activity tools.

Results. The most prominent finding was the higher blood expression of Th17-related cytokines [retinoic acid-related orphan receptor-γ, interferon regulatory factor 4, interleukin (IL)-23A, IL-6, IL-17F, and IL-21] in juvenile DM at baseline. In contrast, adult patients with DM showed increased blood levels of STAT3 and BCL6 compared with juvenile DM. In muscle, GATA3, IL-13, and STAT5B were found at higher levels in juvenile patients with DM compared with adult DM. Among 25 patients (11 adult and 14 juvenile DM) who had blood samples at baseline and at 6 months, increased expression of IL-1β, STAT3, STAT6, STAT5B, and BCL6 was associated with an improvement in global extramuscular disease activity.

Conclusion. We observed differences in gene expression profiling in blood and muscle between new-onset adult and juvenile DM. Cytokine expression in the blood of juvenile patients with new-onset DM was dominated by Th17-related cytokines compared with adult patients with DM. This may reflect the activation of different Th pathways between muscle and blood.

Key Indexing Terms:
  • DERMATOMYOSITIS
  • CD4 T HELPER CELLS
  • CYTOKINES
  • GENE EXPRESSION

Dermatomyositis (DM) is a systemic, inflammatory disorder primarily affecting muscle and skin in children and adults. Although the pathogenesis of adult and juvenile DM appear similar, there are important differences in the clinical features and pathophysiology. Juvenile DM has more cutaneous features such as nailfold telangiectasia and calcinosis with a good outcome in the majority of the cases1, whereas adult DM is more resistant to treatment and complete remission is infrequent with a higher mortality rate2,3,4. Similarly, adult patients with DM have a higher risk of developing cancer, but malignancies are rarely reported in juvenile DM5. Interstitial lung disease is a common occurrence in adult DM in up to 23.8% of cases6, but it is uncommon in juvenile DM.

The cellular infiltrates are reported to be similar in adult and juvenile DM and consist of CD4+ T cells, plasmacytoid dendritic cells, B cells, macrophages, and Th17 cells.

Naive CD4+ T cells develop into functionally mature effector cells upon stimulation with relevant antigenic peptides that induce differentiation into at least 4 major Th lineages including Th1, Th2, Th17, and Foxp3+ Treg cells, which produce lineage-indicating cytokines and perform distinct functions in regulating immunity and inflammation7,8,9. In addition, other Th cell subsets have been recently described, such as follicular Th (TFH) cells, Th9 cells, and interleukin (IL) 22-expressing Th22 cells10,11,12.

The main way that differentiated CD4 T cells regulate inflammation is by the release of cytokines. Cytokines and transcription factors are critical for determining CD4+ T cell fates and the effector cytokine production. For instance, IL-12 induces expression of the transcription factors T-bet (TBX21) and signal transducer activator of transcription 4 (STAT4), which mediates the differentiation of Th1 cells with production of interferon-γ (IFN-γ), IL-2, and tumor necrosis factor-α (TNF-α) and -β, whereas IL-4 induces the transcription factors GATA-binding protein 3 (GATA3) and STAT6 with subsequent differentiation of Th2 cells and production of cytokines IL-4, IL-5, IL-13, and IL-1013,14. Th17 cells express the master transcription regulator retinoic acid-related orphan receptor-γ (RORC) and produce canonical IL-17A and IL-17F cytokines. The cytokines IL-6, IL-21, IL-23, and transforming growth factor-β1 (TGF-β1) are crucial factors for the differentiation of Th17 cells8,15. Cytokine production of these Th subsets can be heterogeneous and overlapping, with individual cells within a given polarized Th population at any 1 timepoint not necessarily secreting the full range of cytokine for that subset16.

Studies concerning cytokine expression in muscle tissue of patients with inflammatory myopathies including DM have shown the dominant presence of IL-1α, TGF-β1, IL-6, and proinflammatory Th1 cytokines (IFN-γ, IL-2), and a weak expression of Th2-derived cytokines17,18,19,20, suggesting a Th1/Th2 balance in muscle tissue with a greater Th1 response in DM. Interestingly, a study showed that CD4+IFN-γ+ cells were decreased whereas the CD4+IL-4+ cells (Th2 cells) were increased in the blood of patients with new-onset DM21, suggesting that Th2 cells may predominate in the blood of active DM. In parallel to Th1 and Th2 cells, studies have begun to elucidate the importance of IL-17–producing Th17 cells in the pathogenesis of myositis18,22,23.

Although it appears that the pathogenesis of DM in adults and children is similar, striking differences in clinical features, outcome, and response to treatment exist and suggest that different mechanisms may be at least partially involved. Only a few studies have previously compared the immunopathological features of adult and juvenile DM; most studies combine these diseases. In our study, we sought to compare mRNA expression differences between adults and children with new-onset DM in genes related to Th cell signaling pathways and/or innate immune response using gene expression profiles obtained from peripheral blood mononuclear cells (PBMC) and affected muscle tissues. We also sought to determine whether changes existed in gene expression profiles between baseline visit and 6 months of followup in both DM groups and how they related to changes in clinical disease activity. The purpose of our study was to extend our previous findings24 to include both gene expression data obtained from blood and affected muscle samples to assess which “pathways” or individual genes were deregulated in juvenile and adult DM.

MATERIALS AND METHODS

Blood samples and clinical data were obtained prospectively from 26 children and 21 adults with new-onset disease (< 6 mos of clinical symptoms) who fulfilled the Bohan and Peter criteria25 for the diagnosis of DM at baseline. Blood samples were available in 25 patients (11 adults and 14 juveniles) at baseline and 6 months. Of the 47 patients, 8 were included in a previous report24 and 39 were new samples. All subjects had a definitive diagnosis of DM and were seen at the Division of Rheumatology at the Mayo Clinic, Rochester, Minnesota. The Mayo Clinic Institutional Review Board approved this study (10-005501), and informed consent was obtained from each participant. Disease activity measures included the extramuscular disease activity, physician’s global activity (PGA), and the manual muscle testing of 8 muscle groups24. PBMC were collected at baseline and at a 6-month followup visit. In addition, paired muscle biopsies were obtained from 7 adults and 8 juvenile patients with DM at baseline visit. Biopsies were obtained from the vastus lateralis in 7 patients (all juvenile DM) and from the deltoid and triceps muscles for 8 (7 adult DM and 1 juvenile DM). These specimens were reviewed and confirmed to be DM by a neuromuscular pathologist (neuromuscular laboratory, Mayo Clinic, Rochester, Minnesota, USA).

Gene expression profiling

Whole blood was collected in tubes treated with an RNA stabilization agent (PAXgene; PreAnalytiX). Total RNA was isolated according to the manufacturer’s protocol with on-column DNase treatment. RNA yield and integrity were assessed using an Agilent Lab-on-a-chip Bioanalyzer (Agilent Technologies Inc.). Muscle was homogenized using a PowerGen 700 (Fisher Scientific) and RNA isolated by an organic extraction method (TRIzol; Life Technologies), and was further purified with RNeasy Mini Kit (Qiagen) and an on-column DNase treatment. We measured mRNA expression of IL-1β, IL-6, IL-23A, IL-27, IL-17A, IL-17D, IL-17F, IL-21, IL-22, RORC, TGF-β1, IFN-γ, TNF-α, IL-2, TBX21, STAT4, IL-4, IL-5, IL-10, IL-12B, IL-13, STAT6, GATA3, interferon regulatory factor 4 (IRF4), forkhead box P3 (FOXP3), STAT5B, IL-10, IL-9, B cell CLL/lymphoma 6 (BCL6), STAT3, lymphotoxin-α (LTA/TNFSF1), and the housekeeping genes GAPDH, B2M, and ACTB using a custom RT2 Profiler PCR Array and amplified on an ABI 7900HT PCR system. The genes we analyzed were grouped in “pathways” or functionally related groups of genes according to the particular cytokines secreted by the individual Th cell subset as well as innate immune cells (Table 1). The transcription factors examined were unique to specific Th cell pathways such as TBX21 (Th1), GATA3 (Th2), RORC (Th17), and FOXP3 (Treg). However, we are aware that most genes can act as part of 1 or more pathways. For instance, IRF4 expression, a transcription factor essential for Th2 effector cell differentiation, is also known to interact with STAT3 to induce RORγt expression, suggesting its effect on Th17 cells26.

View this table:
  • View inline
  • View popup
Table 1.

Functional grouping of genes analyzed in blood and muscle tissue of adult and juvenile patients with dermatomyositis.

Statistical analysis

Data are expressed as the median (range) where indicated. A Wilcoxon rank sum test was performed for comparisons between 2 groups (e.g., adult vs juvenile DM). Paired Student t tests were performed to compare gene expression levels between baseline and 6 months as well as between blood and muscle samples. Spearman correlation coefficients were used to examine correlations between variables. P values < 0.05 were considered statistically significant. Multiple comparisons involved a maximum of 30 comparisons for any specific hypothesis; thus, the Bonferroni correction would consider p values < 0.0017 to be significant. Analyses were performed using SAS version 9.3 (SAS Institute Inc.) and R 3.1.1 (R Foundation for Statistical Computing).

RESULTS

Demographic and clinical characteristics of the patients with DM

Demographic and clinical characteristics of the patients with DM are summarized in Table 2. At baseline, patients in both groups had similar disease activity as evidenced by the values for the disease activity core measures. Ten adult patients with DM (48%) and 6 juvenile patients with DM (29%) had begun treatment with 1 or more traditional disease-modifying antirheumatic drugs (DMARD) in the 2 months prior to the baseline visit. Concomitant corticosteroid use was reported for 14 adults (70%) and 8 children (38%) with DM.

View this table:
  • View inline
  • View popup
Table 2.

Characteristics at baseline of adult and juvenile patients with DM. Values are mean ± SD unless otherwise specified.

Overall, these patients improved substantially on all disease activity measures between baseline and the 6-month followup visit, with a median improvement of 20/100 in the extramuscular visual analog scale (VAS), 22/100 in the muscle VAS, and 34/100 in the global VAS. Changes in disease activity measures were not significantly different between adults and children with DM (p = 0.14, p = 0.51, and p = 0.07 for PGA, muscle activity, and extramuscular disease activity VAS scores, respectively).

T cell lineage gene expression in blood of new-onset adult and juvenile DM

We investigated whether the T cell lineage gene expression profiling in blood would reveal distinct T cell pathways in juvenile versus adult DM. Gene expression levels of RORC/RORγt, the master regulator for Th17 cells, and IRF4, another transcription factor required for Th17 cell differentiation, were significantly increased in blood of juvenile compared with adult patients with DM at baseline (p = 0.001 and p < 0.001, respectively; Figure 1). In addition, juvenile DM had significantly higher levels of IL-23A (p < 0.001), IL-6 (p < 0.001), IL-17F (p = 0.005), and IL-21 (p = 0.012) mRNA at the baseline visit when compared with adult patients with DM. Similarly, FOXP3 and STAT4 gene levels were significantly increased in the blood of juvenile DM compared with adult DM (p = 0.016 and p = 0.009, respectively). In adult DM blood, increased levels of STAT3 and BCL6 were observed compared with juvenile DM blood (p = 0.028 and p = 0.002, respectively; Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Gene expression profile in peripheral blood mononuclear cells of adult and juvenile patients with DM at baseline. The plot depicts the gene expression data from genes that were differentially expressed in blood between juvenile and adult DM. P values < 0.05 were considered statistically significant. Genes expressed as relative quantification. DM: dermatomyositis; JDM: juvenile DM.

T cell lineage gene expression in affected muscle of patients with new-onset DM

As a step toward understanding the differences between juvenile and adult DM, we analyzed gene expression in paired muscle biopsies collected from 15 patients with DM (7 adults and 8 children) at baseline. All DM samples were analyzed histologically to confirm DM. Perivascular lymphocytic infiltration was seen in all DM samples. A gene expression profile was also evaluated in the skeletal muscle tissues from otherwise healthy patients undergoing an orthopedic procedure. The majority of transcripts were found at higher levels in affected muscle tissue of both adult and juvenile DM compared with normal muscle tissues (data not shown).

Evidence of Th2 T cells in muscle tissue was demonstrated by increased expression levels of GATA3 (p = 0.004) and IL-13 (p = 0.049), and Treg cells by increased STAT5B expression (p = 0.049) in affected muscle of juvenile compared with adult patients with DM.

Correlation of T cell lineage gene expression with medication use in patients with DM

Glucocorticoids are critical regulators of several inflammatory cytokines27,28, but our previous data on cytokine protein levels suggest that glucocorticoid treatment does not statistically alter the levels except for IL-1β24. Herein, we analyzed the association between glucocorticoid treatment and the expression of transcription factors. GATA3, IRF4, and FOXP3 levels were lower in juvenile DM blood from patients who were receiving glucocorticoids versus those not taking glucocorticoids (p = 0.015, p = 0.001, and p < 0.001, respectively). If we looked at just patients (both juvenile and adult DM) who were taking glucocorticoids, IL-23A, IL-6, RORC, IRF4, and BCL6 gene expression levels remained significant when comparing juvenile and adult DM; however, other comparisons that no longer reached statistical significance were marginal: IL-17F (p = 0.056), IL-21 (p = 0.12), STAT4 (p = 0.088), and FOXP3 (p = 0.056), which could be related to the limited sample size. Only STAT3 was clearly no longer significant (p = 0.45).

Correlation of blood gene expression profiles with clinical features in juvenile and adult DM at baseline and at 6-month followup visit

To examine whether differential gene expression was associated with DM disease activity, we compared expression with disease activity at baseline, and examined whether changes in gene expression correlated with changes in the disease activity over time. At baseline in the adults, the gene expression levels of these were found to correlate significantly with muscle disease activity measured at baseline (Figure 2): IL-23A (p = 0.033), RORC (p < 0.001), TGF-β1 (p = 0.035), IL-27 (p = 0.003), IL-22 (p = 0.006), GATA3 (p = 0.045), IRF4 (p < 0.001), IL-4 (p < 0.001), IL-13 (p < 0.001), IFN-γ (p = 0.003), TNF-α (p < 0.001), STAT4 (p = 0.006), and FOXP3 (p = 0.032). Among adults, levels of RORC (p < 0.001), IFN-γ (p = 0.008), STAT4 (p = 0.011), IL-4 (p = 0.009), and IL-13 (p < 0.001) were found to correlate significantly with PGA at baseline and only RORC (p = 0.045) correlated significantly with extramuscular disease activity. In contrast, at baseline in the juvenile DM group, gene expression levels of RORC (p = 0.042), IL-17F (p = 0.040), GATA3 (p = 0.044), and STAT4 (p < 0.001) were found to correlate significantly with muscle disease activity measured at baseline (Figure 2). Only RORC (p = 0.018) and STAT4 (p = 0.001) correlated significantly with global disease activity among the juvenile DM and no significant correlations with extramuscular disease were found.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Correlation of mRNA expressions of T cell lineage transcription factors against measures of disease activity (global, muscular, and extramuscular) cytokines in whole blood of juvenile and adult patients with DM. The 2 leftmost panels correlate baseline gene expression values with baseline disease activity measures. The 2 rightmost panels correlate changes in gene expression from baseline to the 6-month visit with changes in disease activity measures over the same period. Negative correlations between changes in gene expression and changes in disease activity indicate that improvements in disease activity were associated with increases in gene expression levels. ADM: adult dermatomyositis; JDM: juvenile dermatomyositis.

Followup data were available in a total of 25 patients (11 adult and 14 juvenile DM). Among the adults, changes in IL-17D (p = 0.048) between baseline and the 6-month visit were positively correlated with changes in global extramuscular disease activity, indicating that improved disease activity was associated with decreases in gene expression levels (Figure 2). Among the juvenile patients with DM, changes in STAT6 (p = 0.044), IL17-D (p = 0.010), and BCL6 (p = 0.009) correlated negatively with changes in global extramuscular disease activity. No significant correlations between changes in gene expression levels and changes in muscle or PGA measures were found for either group.

Associations between changes in treatment from baseline to 6 months and cytokine gene expression levels were examined longitudinally in the adult and juvenile DM groups combined to enhance statistical power. The addition of DMARD (n = 22) was associated with increased levels of IL-1β (p = 0.012), STAT3 (p = 0.005), STAT6 (p = 0.001), and STAT5B (p = 0.037), and decreased levels of IFN-γ (p = 0.027), IL-22 (p = 0.044), and IRF4 (p = 0.023). Use of glucocorticoids (n = 21) was associated with increases in FOXP3 (p = 0.020), IL-23A (p = 0.013), IRF4 (p = 0.013), and TGF-β1 (p = 0.022), and decreases in IL-2 (p = 0.017). Comparisons of cytokines and transcription factors between blood and muscle did now show significant differences (data not shown).

DISCUSSION

Classically, immunohistochemical and molecular (i.e., real-time PCR) analyses in DM muscle show predominant expression of macrophage-derived cytokines (i.e., IL-1, TNFSF1, and TNF-α), as well as cytokines that can originate from either T cells or macrophages (i.e., IL-6 and TGF-β1)29,30,31. Further, current evidence increasingly supports alternative pathogenic mechanisms, including both adaptive and innate immune-mediated responses. An innate immune response characterized by infiltration of plasmacytoid dendritic cells in DM muscle lesions and IFN-α/β–inducible gene signature in whole blood and muscle may be an important part of the pathogenesis of DM17,32,33,34,35,36.

At present, PCR-based arrays allow facile analysis of expression of a relatively large number of pathway- or disease-focused genes with remarkable sensitivity. Here, we analyzed the expression profile of 30 genes in whole blood from 47 individuals with newly diagnosed DM and in 15 paired muscle samples. To our knowledge, our study constitutes the most comprehensive analysis contrasting the gene expression signatures between adults and children with DM to date.

Cellular and protein effectors of innate and adaptive immunity are found in the blood and inflamed muscle lesions of patients with DM, and an increasing body of evidence indicates that they are directly involved in myofiber injury32,37. We have previously identified a strong correlation between IL-6 serum levels and Type I IFN signature in adult and juvenile DM23. Similarly, a strong expression of IL-1α, IL-1β, TGF-β, and TNF-α has been observed in the affected muscle of patients with DM and other types of myositis, suggesting that these cytokines are important contributors to the pathogenesis of DM19,38,39,40. On the side of the adaptive immune system, despite that muscle-infiltrating T cells are predominantly CD4+ T cells in both adults and children with DM, Th1-derived cytokine IFN-γ and Th2-derived cytokine IL-4 are less abundantly expressed compared with other cytokines30,41, suggesting that other effector T cell lineages might be involved in the pathogenesis or the possible perpetuation of the inflammatory response in DM. Although juvenile and adult DM have a set of common genetic risk alleles and abnormalities in both B and T cell functions, they also have important differences in clinical features and associated disorders, suggesting that specific immunological aberrations may differ for each disease. Our combined analysis of gene expression data in peripheral blood and muscle tissues obtained simultaneously provides a deeper understanding of the T cell pathways that regulate the pathogenesis of both myositis subsets, a finding that eventually could lead to new strategies to facilitate improvement of the therapy.

Herein, we observed differences in gene expression profiling in the blood between juvenile and adult patients with DM. The gene expression profiling that we found in the blood of juvenile patients with DM indicates a Th17 type of inflammatory process. The proportion of patients using glucocorticoids at baseline was higher in adult DM. Despite this difference, after adjusting for glucocorticoid use, we found that IL-23A, IL-6, RORC, and IRF4 gene expression levels remained significantly different in juvenile DM compared with adult DM. The upregulation of Th2-related genes was apparent in the affected muscle of juvenile patients with DM compared with adult DM. However, the interpretation of gene expression profiling in muscle biopsies can be affected by several factors such as a small amount of muscle tissue or the variability of biopsy sampling of inflammatory cells.

Our study also examined the effect of DMARD and glucocorticoid use on the cytokine levels from baseline to 6-month followup. Use of DMARD was associated with increases in blood levels of IL-1B, STAT3, STAT6, and STAT5B, and with decreases in blood levels of IFN-γ, IL-22, and IRF4. Use of glucocorticoids was associated with increases in blood levels of FOXP3, IL-23A, IRF4, and TGF-β1, and with decreases in IL-2, suggesting that various potential immune pathways are altered with treatment.

In addition to the cytokines they produce, effector T cells can be distinguished by their differential expression of specific transcription factors and STAT proteins, which induce gene expression of distinct inflammatory pathways. However, although 1 transcription factor might be the predominant initiator of a differentiation pathway, effector T cells might respond to additional cytokines such as IL-2, IL-6, and IL-21 within the inflammatory environment, which might activate additional T cell lineages. For instance, FOXP3+ Tregs can produce IL-17 when activated in the presence of IL-1β and IL-6, losing their suppressive activity and promoting inflammation42. Additionally, there is much more T cell plasticity than previously recognized wherein a transcription factor may be involved in more than 1 particular differentiation pathway. For example, a study showed that TBX21 (Th1 lineage) and RORC (Th17 lineage) transcription factors were found to be expressed in Th17- and Th1-like Treg cells, respectively43.

In our study, in addition to increased expression of Th17 cytokine genes, RORC and IRF4 (both with critical involvement in Th17 development) were increased in juvenile DM blood compared with adult DM blood. FOXP3 (Tregs) and STAT4 (Th1) gene levels were also elevated in juvenile DM blood.

In contrast, we found higher expression of BCL6 in adult DM blood compared with juvenile DM, which remained significant after adjusting for glucocorticoid use. We observed that STAT3 expression was higher in adult DM blood compared with juvenile DM, although not significant after adjusting for glucocorticoid use. STAT3 is a critical factor for not only activating the proinflammatory Th17 lineage, but for promoting BCL6 transcription and TFH differentiation44. TFH cells are required for germinal center formation, and studies have indicated that TFH is critical in the pathogenic autoantibody production of several autoimmune diseases45,46. BCL6 is upregulated in TFH cells and is considered a master regulator for this lineage. TFH cells have been documented in peripheral blood of juvenile and adult patients with DM47,48. Additionally, we have previously shown that CD4+ T cells and activated B cells come together in ectopic lymphoid aggregates in affected muscle tissue of juvenile patients with DM34, and others have documented similar findings in adult DM49. Together, it seems likely that circulating TFH cells could migrate and local TFH cell-B cell interactions in inflamed muscle tissue may contribute to extranodal immune activation.

In addition to its established role as a transcription factor in TFH differentiation, IL-6–Janus kinase and signal transducer and activator of transcription 3 (JAK-STAT3) activation in muscle cells is strongly associated with skeletal muscle wasting in cancer and other conditions associated with high IL-6 levels50. Cancer and muscle wasting are common features in adult patients with DM; however, whether the IL-6–JAK-STAT3 pathway is a primary mediator of these clinical manifestations in adults with DM needs further investigation.

The differences in gene expression profiling found between juvenile and adult DM can subsequently be applied to gain a better understanding of the complex cellular components involved in the pathogenesis. This can be applied to further studies using emerging technologies such as single cell analysis of circulating immune cell subset and/or molecular analysis of selected cell aggregates in affected muscle tissue using laser identification microdissection. Those analyses could clarify which pathways are shared between juvenile and adult DM, and which differ, identifying particular immune pathways that are active in subsets of patients with DM leading to individualized patient treatment.

Acknowledgment

We thank Jane Jaquith, Heidi Hanf, Jenni Sletten, and Fran Anderson for their efforts in identifying and recruiting patients; and Dr. Andrew G. Engel, Julianna Berge, and Abby Kaehler for their assistance in collecting muscle biopsies.

Footnotes

  • Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (5R01AR057781-04), the National Center for Advancing Translational Science (NCATS; UL1 TR000135), and the Mayo Foundation for Medical Education and Research.

  • Accepted for publication September 30, 2016.

REFERENCES

  1. 1.↵
    1. Ramanan AV,
    2. Feldman BM
    . Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002;28:833–57.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Christopher-Stine L,
    2. Plotz PH
    . Adult inflammatory myopathies. Best Pract Res Clin Rheumatol 2004;18:331–44.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Hochberg MC,
    2. Feldman D,
    3. Stevens MB
    . Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986;15:168–78.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Rider LG
    . Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:935–77.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Wakata N,
    2. Kurihara T,
    3. Saito E,
    4. Kinoshita M
    . Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 2002;41:729–34.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Marie I,
    2. Hatron PY,
    3. Dominique S,
    4. Cherin P,
    5. Mouthon L,
    6. Menard JF
    . Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011;63:3439–47.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Mosmann TR,
    2. Cherwinski H,
    3. Bond MW,
    4. Giedlin MA,
    5. Coffman RL
    . Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348–57.
    OpenUrlAbstract
  8. 8.↵
    1. Harrington LE,
    2. Hatton RD,
    3. Mangan PR,
    4. Turner H,
    5. Murphy TL,
    6. Murphy KM,
    7. et al.
    Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123–32.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Wing K,
    2. Sakaguchi S
    . Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11:7–13.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Schaerli P,
    2. Willimann K,
    3. Lang AB,
    4. Lipp M,
    5. Loetscher P,
    6. Moser B
    . CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000;192:1553–62.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Zheng Y,
    2. Danilenko DM,
    3. Valdez P,
    4. Kasman I,
    5. Eastham-Anderson J,
    6. Wu J,
    7. et al.
    Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648–51.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Stassen M,
    2. Schmitt E,
    3. Bopp T
    . From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci 2012;1247:56–68.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Dong C
    . Helper T-cell heterogeneity: a complex developmental issue in the immune system. Cell Mol Immunol 2010;7:163.
    OpenUrlPubMed
  14. 14.↵
    1. Oestreich KJ,
    2. Weinmann AS
    . Master regulators or lineage-specifying? Changing views on CD4+ T cell transcription factors. Nat Rev Immunol 2012;12:799–804.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Park H,
    2. Li Z,
    3. Yang XO,
    4. Chang SH,
    5. Nurieva R,
    6. Wang YH,
    7. et al.
    A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133–41.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Kelso A,
    2. Groves P,
    3. Ramm L,
    4. Doyle AG
    . Single-cell analysis by RT-PCR reveals differential expression of multiple type 1 and 2 cytokine genes among cells within polarized CD4+ T cell populations. Int Immunol 1999;11:617–21.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Page G,
    2. Chevrel G,
    3. Miossec P
    . Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004;50:199–208.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Chevrel G,
    2. Granet C,
    3. Miossec P
    . Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis 2005;64:1257–62.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Lundberg I,
    2. Ulfgren AK,
    3. Nyberg P,
    4. Andersson U,
    5. Klareskog L
    . Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865–74.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Tucci M,
    2. Quatraro C,
    3. Dammacco F,
    4. Silvestris F
    . Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 2006;146:21–31.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Ishii W,
    2. Matsuda M,
    3. Shimojima Y,
    4. Itoh S,
    5. Sumida T,
    6. Ikeda S
    . Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med 2008;47:1593–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Chevrel G,
    2. Page G,
    3. Granet C,
    4. Streichenberger N,
    5. Varennes A,
    6. Miossec P
    . Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003;137:125–33.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Bilgic H,
    2. Ytterberg SR,
    3. Amin S,
    4. McNallan KT,
    5. Wilson JC,
    6. Koeuth T,
    7. et al.
    Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009;60:3436–46.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Reed AM,
    2. Peterson E,
    3. Bilgic H,
    4. Ytterberg SR,
    5. Amin S,
    6. Hein MS,
    7. et al.
    Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012;64:4078–86.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Bohan A,
    2. Peter JB
    . Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Hu CM,
    2. Jang SY,
    3. Fanzo JC,
    4. Pernis AB
    . Modulation of T cell cytokine production by interferon regulatory factor-4. J Biol Chem 2002;277:49238–46.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. O’Shea JJ,
    2. Murray PJ
    . Cytokine signaling modules in inflammatory responses. Immunity 2008;28:477–87.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Rogatsky I,
    2. Ivashkiv LB
    . Glucocorticoid modulation of cytokine signaling. Tissue Antigens 2006;68:1–12.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Lepidi H,
    2. Frances V,
    3. Figarella-Branger D,
    4. Bartoli C,
    5. Machado-Baeta A,
    6. Pellissier JF
    . Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 1998;24:73–9.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Lundberg I,
    2. Brengman JM,
    3. Engel AG
    . Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995;63:9–16.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. De Bleecker JL,
    2. Meire VI,
    3. Declercq W,
    4. Van Aken EH
    . Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999;9:239–46.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Greenberg SA,
    2. Pinkus JL,
    3. Pinkus GS,
    4. Burleson T,
    5. Sanoudou D,
    6. Tawil R,
    7. et al.
    Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664–78.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. López de Padilla CM,
    2. Vallejo AN,
    3. McNallan KT,
    4. Vehe R,
    5. Smith SA,
    6. Dietz AB,
    7. et al.
    Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007;56:1658–68.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. López De Padilla CM,
    2. Vallejo AN,
    3. Lacomis D,
    4. McNallan K,
    5. Reed AM
    . Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009;60:1160–72.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Niewold TB,
    2. Kariuki SN,
    3. Morgan GA,
    4. Shrestha S,
    5. Pachman LM
    . Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009;60:1815–24.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Baechler EC,
    2. Bilgic H,
    3. Reed AM
    . Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011;13:249.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Salajegheh M,
    2. Kong SW,
    3. Pinkus JL,
    4. Walsh RJ,
    5. Liao A,
    6. Nazareno R,
    7. et al.
    Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010;67:53–63.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Nyberg P,
    2. Wikman AL,
    3. Nennesmo I,
    4. Lundberg I
    . Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000;27:940–8.
    OpenUrlPubMed
  39. 39.↵
    1. Grundtman C,
    2. Salomonsson S,
    3. Dorph C,
    4. Bruton J,
    5. Andersson U,
    6. Lundberg IE
    . Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007;56:674–87.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Mamyrova G,
    2. O’Hanlon TP,
    3. Sillers L,
    4. Malley K,
    5. James-Newton L,
    6. Parks CG,
    7. et al;
    8. Childhood Myositis Heterogeneity Collaborative Study Group
    . Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008;58:3941–50.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Tews DS,
    2. Goebel HH
    . Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996;55:342–7.
    OpenUrl
  42. 42.↵
    1. Beriou G,
    2. Costantino CM,
    3. Ashley CW,
    4. Yang L,
    5. Kuchroo VK,
    6. Baecher-Allan C,
    7. et al.
    IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009;113:4240–9.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Duhen T,
    2. Duhen R,
    3. Lanzavecchia A,
    4. Sallusto F,
    5. Campbell DJ
    . Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 2012;119:4430–40.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Nurieva RI,
    2. Chung Y,
    3. Hwang D,
    4. Yang XO,
    5. Kang HS,
    6. Ma L,
    7. et al.
    Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008;29:138–49.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Hale JS,
    2. Ahmed R
    . Memory T follicular helper CD4 T cells. Front Immunol 2015;6:16.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Liu X,
    2. Nurieva RI,
    3. Dong C
    . Transcriptional regulation of follicular T-helper (Tfh) cells. Immunol Rev 2013;252:139–45.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Morita R,
    2. Schmitt N,
    3. Bentebibel SE,
    4. Ranganathan R,
    5. Bourdery L,
    6. Zurawski G,
    7. et al.
    Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 2011;34:108–21.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Espinosa-Ortega F,
    2. Gómez-Martin D,
    3. Santana-De Anda K,
    4. Romo-Tena J,
    5. Villaseñor-Ovies P,
    6. Alcocer-Varela J
    . Quantitative T cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic subsets. Clin Exp Immunol 2015;179:520–8.
    OpenUrl
  49. 49.↵
    1. De Bleecker JL,
    2. Engel AG,
    3. Butcher EC
    . Peripheral lymphoid tissue-like adhesion molecule expression in nodular infiltrates in inflammatory myopathies. Neuromuscul Disord 1996;6:255–60.
    OpenUrlPubMed
  50. 50.↵
    1. Bonetto A,
    2. Aydogdu T,
    3. Jin X,
    4. Zhang Z,
    5. Zhan R,
    6. Puzis L,
    7. et al.
    JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012;303:E410–21.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 44, Issue 1
1 Jan 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis
Consuelo M. López De Padilla, Cynthia S. Crowson, Molly S. Hein, Richard S. Pendegraft, Michael A. Strausbauch, Timothy B. Niewold, Floranne C. Ernste, Erik Peterson, Emily C. Baechler, Ann M. Reed
The Journal of Rheumatology Jan 2017, 44 (1) 117-124; DOI: 10.3899/jrheum.160293

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis
Consuelo M. López De Padilla, Cynthia S. Crowson, Molly S. Hein, Richard S. Pendegraft, Michael A. Strausbauch, Timothy B. Niewold, Floranne C. Ernste, Erik Peterson, Emily C. Baechler, Ann M. Reed
The Journal of Rheumatology Jan 2017, 44 (1) 117-124; DOI: 10.3899/jrheum.160293
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

DERMATOMYOSITIS
CD4 T HELPER CELLS
CYTOKINES
GENE EXPRESSION

Related Articles

Cited By...

More in this TOC Section

  • Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs
  • Increasing Cases of Chronic Nonbacterial Osteomyelitis in Children: A Series of 215 Cases From a Single Tertiary Referral Center
  • Occurrence and Risk Factors of Uveitis in Juvenile Psoriatic Arthritis: Data From a Population-based Nationwide Study in Germany
Show more Pediatric Rheumatology

Similar Articles

Keywords

  • dermatomyositis
  • CD4 T HELPER CELLS
  • cytokines
  • GENE EXPRESSION

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire